



| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

| | |
|-------------------------------------|--|
| Adopted By PBSL | |
| Start of public Consultation | |
| End of public Consultation | |
| Agreed by QMS committee | |
| Approved by Board | |

Pharmacy Board of Sierra Leone
PMB 322
Central Medical Stores Compound
New England Ville
Freetown





| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

Table of Contents

| | |
|---------------------------------------|---|
| ACKNOWLEDGEMENTS..... | 3 |
| EXECUTIVE SUMMARY..... | 3 |
| 1.0 INTRODUCTION..... | 3 |
| 2.0 OBJECTIVE..... | 3 |
| 3.0 SCOPE..... | 3 |
| 4.0 SPECIFIC REQUIREMENTS..... | 3 |
| 4.1 Category of Client | 3 |
| 4.2 Guidelines | 4 |
| 4.3 Sample size requirements | 4 |
| 4.4 Registration Samples..... | 6 |
| 4.5 Non – pharmacopoeial samples..... | 6 |
| 4.6 Drug Donation samples..... | 6 |
| 4.7 Laboratory Analysis | 7 |
| 5.0 GLOSSORY..... | 8 |
| 6.0 REFERENCES..... | 8 |
| 7.0 ANNEXES | 8 |

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

ACKNOWLEDGEMENTS

EXECUTIVE SUMMARY

1.0 INTRODUCTION

These guidelines are intended to assist applicants in submitting samples to the National Pharmaceutical Quality Control Laboratory (NPQCL), Pharmacy Board of Sierra Leone (PBSL) for evaluation.

2.0 OBJECTIVE

To check the integrity of samples and the validity of analytical results that are required to ensure certain conditions exist upon receipt of samples by the laboratory.



3.0 SCOPE

All samples received by the lab for laboratory analysis

4.0 SPECIFIC REQUIREMENTS

4.1 Category of Client

The departments of the Pharmacy Board of Sierra Leone is the major client of the National Pharmaceutical Quality Control Laboratory. All clients are required to fill a sample analysis request form which is available at Registration or Drug Information & Pharmacovigilance or Inspection Departments of the Pharmacy Board of Sierra Leone.

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

4.2 Guidelines

The following requirements must be met when submitting samples to the Laboratory.

4.2.1 Sample packaging requirements

Samples must be submitted in the appropriate properly sealed and labeled containers.

4.2.2 Sample identification requirements



Samples submitted for analysis shall be accompanied by a test request form duly filled by the inspector and shall contain the following information:

- Sample code
- Product name
- Product label claim
- Product Lot number/Batch number
- Sample size (Quantity in a package/pack size)
- Date of manufacture
- Date of Expiry
- Manufacturer's name and address
- Storage conditions
- Tests requested
- Laboratory number
- Name, Signature, Designation of responsible person for the request and date

4.3 Sample size requirements

The size of sample is dependent on;

- The type and number of tests requested,

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |



- The reason for the request which could vary from reasons such as batch release, registration, post marketing surveillance, tenders or counterfeits.

The minimum number of samples to be submitted to the NPQCL for new registration is indicated in the table below:

| FORMULATION | PACK SIZE | MINIMUM NO. OF SAMPLES REQUIRED |
|--------------------------|------------------|----------------------------------------|
| Tablets/capsules | All | 120 Tablets/Capsules |
| Suspension/Syrups | ≤ 50mL | 50 Bottles |
| | 50mL | 50 Bottles |
| | 100mL | 50 Bottles |
| Injectables | ≤ 10mL | 100 Vials/Ampoules |
| | 10 – 100mL | 50 Vials/Ampoules/Bottles |
| | ≥ 100mL | 50 Bottles |
| Creams/Ointments/Lotions | ≤ 5g | 50 Tubes |
| | 5 – 50g | 50 Tubes/Jars |
| | ≥ 50g | 50 Tubes/Jars |
| | < 10mL | 50 Bottles |
| | 10 – 100mL | 50 Bottles |
| Inhalers | All | 10 Packs |
| Raw material | All | 5g |
| ORS | All | 50 Packs |

For submission of Samples for Post Market Surveillance, the minimum number of samples to be submitted are:

| FORMULATION | PACK SIZE | MINIMUM NO. OF SAMPLES REQUIRED |
|--------------------|------------------|----------------------------------------|
|--------------------|------------------|----------------------------------------|

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

| | | |
|--------------------------|------------|---------------------------|
| Tablets/capsules | All | 120 Tablets/Capsules |
| Suspension/Syrups | ≤ 50mL | 20 Bottles |
| | 50mL | 6 Bottles |
| | 100mL | 6 Bottles |
| Injectables | ≤ 10mL | 100 Vials/Ampoules |
| | 10 – 100mL | 50 Vials/Ampoules/Bottles |
| | ≥ 100mL | 10 Bottles |
| Creams/Ointments/Lotions | ≤ 5g | 50 Tubes |
| | 5 – 50g | 20 Tubes/Jars |
| | ≥ 50g | 5 Tubes/Jars |
| | < 10mL | 100 Bottles |
| | 10 – 100mL | 50 Bottles |
| Inhalers | All | 10 Packs |
| Raw material | All | 5g |
| ORS | All | 30 Packs |

4.4 Registration Samples

All samples should have at least two-thirds of their shelf life remaining at the time of receipt.



4.5 Non – pharmacopoeial samples

These samples must be accompanied with:

- The manufacturer's methods of analysis including finished product specifications and validation data;
- Chemical reference substances together with their certificates of analysis.

4.6 Drug Donation samples

Pharmaceutical products donated through good will or Disaster management should be submitted to the laboratory accompanied

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

with relevant documentation from the Director of Drugs and Medical Supplies and Pharmacy Board of Sierra Leone.

4.7 Laboratory Analysis

4.7.1 Time frame for analysis

The usual duration for completing evaluation on a sample is 2 – 4 weeks.

However this duration may vary from one sample to another.
No client is allowed to communicate directly with analysts.

4.7.2 Payments

All payments by private clients must be made through the office of the Registrar, Pharmacy Board of Sierra Leone.

Upon request, detailed report is issued to the client with an added fee of 20% of the total cost of analysis.



Only one certificate of analysis (COA) is issued per sample and certified copies are provided at an additional cost.

All Payments shall be made in cash or banker's cheques or company cheques and are made payable to the **Pharmacy Board of Sierra Leone**.

4.7.3 Analysis Report

Analytical results are reported in the form of an official certificate which must bear manager, supervisor and the analyst signature with the laboratory stamp.

Where different batches are submitted, each batch is treated as an independent sample and hence each is issued with its own

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

certificate of analysis. In the case of post market surveillance, the same batch collected from different areas will be analysed as different samples

4.8 Appeals

Clients that are dissatisfied with the analytical report issued should contact the office of the Registrar for guidance on the appropriate procedure for handling complaints.

Disclaimer: Transportation of samples to the National Pharmaceutical Quality Control Laboratory;

It is the responsibility of the client to ensure safe transport of samples to the Laboratory, unless under specific cases the laboratory assumes the responsibility of transporting the samples for analysis. In the latter, the client shall make the request in writing and bears the cost of such an exercise.

Samples that require thermal preservation must be transported on ice pack and cooling at the time of receipt.

The institution reserves the right to accept or reject samples if any of the above condition(s) are not met.

5.0 GLOSSORY



NONE

6.0 REFERENCES

NONE

7.0 ANNEXES

NONE

| | | |
|----------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------------------|
|  | Title: Guideline for receipt of samples in the laboratory |  |
| Rev No: 01 | Doc No: PBSL/GL/020 | Version #: 02 |
| Issue date: 15 may 2024 | Effective date: 17 Feb 2024 | Approved by: Registrar |

Prepared by

Reviewed by

Approved by

Head of Lab

Dr Alphan Tejan-Kella
Komeh

Head, Quality Assurance

Dr Michael Lahai

Registrar

Dr James P.